Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: A sub-analysis of GISSI-HF trial

Pulmonary Pharmacology and Therapeutics

Volumn 44, Issue , 2017, Pages 16-23

  Rossi, Andrea ^a,b,c   Inciardi, Riccardo M ^c   Temporelli, Pier Luigi ^d   Lucci, Donata ^e   Gonzini, Lucio ^e   Marchioli, Roberto ^f   Nicolosi, Gian Luigi ^g   Tavazzi, Luigi ^h  

^a UNIVERSITY OF VERONA   (Italy)

^b AIPO   (Italy)

^c University/General Hospital of Verona   (Italy)

^d IRCCS   (Italy)

^e ANMCO RESEARCH CENTER   (Italy)

^f IQVIA   (United States)

^g S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^h MARIA CECILIA HOSPITAL   (Italy)

Author keywords

Chronic heart failure; Chronic obstructive pulmonary disease; Pleiotropic effects; Statin

Indexed keywords

ROSUVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PACEMAKER IMPLANTATION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SMOKING; CHRONIC DISEASE; CLINICAL TRIAL; COMPLICATION; DOUBLE BLIND PROCEDURE; HOSPITALIZATION; INFLAMMATION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; ROSUVASTATIN CALCIUM; TREATMENT OUTCOME;

EID: 85014871967     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2017.03.001     Document Type: Article

References (33)

1. [1] Murray, C.J.L., Lopez, A.D., Measuring the global burden of disease. N. Eng. J. Med. 369 (2013), 448–457.
2. [2] Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2017 Report www.goldcopd.org Accessed Februray 27, 2017.
3. [3] Bafadhel, M., Russell, E.K., Are COPD and cardiovascular disease fundamentally intertwined?. Our Respire J. 47 (2016), 1307–1309.
4. [4] Le Jemtel, T.H., Padeletti, M., Jelic, S., Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J. Am. Coll. Cardiol. 49 (2007), 171–180.
5. [5] Van den Berg, M.E., Striker, B.H., Brusselle, G.G., Larousse, L., Chronic obstructive pulmonary disease and sudden cardiac death: a systematic review. Trends Cardiovasc Med. 26 (2016), 606–613.
6. [6] de Miguel Diez, J., Chancafe Morgan, J., Jiménez García, R., The association between COPD and hearth failure risk: a review. Int. J. Chron. Obstruct Pulmon Dis. 8 (2013), 305–312.
7. [7] Canepa, M., Temporelli, P.L., Rossi, A., Rossi, A., Gonzini, L., Nicolosi, G.L., Staszewsky, L., Marchioli, R., Maggioni, A.P., Tavazzi, L., GISSI-HF Investigators. Prevalence and prognostic impact of chronic obstructive pulmonary disease in patients with chronic heart failure. Data from the GISSI-HF trial. Cardiology 136 (2016), 128–137.
8. [8] Cazzola, M., Rogliani, P., Matera, M.G., Escalation and de-escalation of therapy in COPD: myths, realities and perspectives. Drugs 75 (2015), 1575–1585.
9. [9] Calverley, P.M.A., Knowing when to stop: inhaled corticosteroids in COPD. Eur. Respire J. 46 (2015), 1236–1238.
10. [10] Suissa, S., Rossi, A., Weaning from inhaled corticosteroids in COPD: the evidence. Eur. Respir. J. 46 (2015), 1232–1235.
11. [11] Wedzicha, J.A., Calverley, P.M., Rabe, K.F., Roflumilast: a review of its use in the treatment of COPD. Int. J. Chron. Obstruct Pulmon Dis. 11 (2016), 81–90.
12. [12] Calverley, P.M., Anderson, J.A., Celli, B., Ferguson, G.T., Jenkins, C., Jones, P.W., Yates, J.C., Vestbo, J., TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356 (2007), 775–789.
13. [13] Celli, B., Decramer, M., Kesten, S., Liu, D., Mehra, S., Tashkin, D.P., UPLIFT Study Investigators. Mortality in the 4-year trial on tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am. J. Respire Crit. Care Med. 180 (2009), 948–955 13.
14. [14] Lahousse, L., Loyh, D.W., Joos, G.F., Hofman, A., Leuvens, H.G.M., Brusselle, G., Striker, B.H., Statins, systemic inflammation and risk of death in COPD: the Rotterdam study. Pulm. Pharmacol. Ther. 26 (2013), 212–217.
15. [15] Janda, S., Park, K., FitzGerald, J.M., Etminan, M., Swiston, J., Statins in COPD: a systematic review. Chest 136 (2009), 734–743.
16. [16] Criner, G.J., Connett, J.E., Aaron, S.D., Albert, R.K., Bailey, W.C., Casaburi, R., Cooper, J.A. Jr., Curtis, J.L., Dransfield, M.T., Han, M.K., Make, B., Marchetti, N., Martinez, F.J., Niewoehner, D.E., Scanlon, P.D., Sciurba, F.C., Scharf, S.M., Sin, D.D., Voelker, H., Washko, G.R., Woodruff, P.G., Lazarus, S.C., COPD clinical research network; canadian institutes of health research. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N. Engl. J. Med. 370 (2014), 2201–2210.
17. [17] Soler-Cataluna, J.J., Martinez-Garcia, M.A., Roman Sanchez, P., Salcedo, E., Navarro, M., Ochado, R., Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60 (2005), 925–931.
18. [18] Tavazzi, L., Maggioni, A.P., Marchioli, R., Barlera, S., Franzosi, M.G., Latini, R., Lucci, D., Nicolosi, G.L., Porcu, M., Tognoni, G., Effect rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008), 1231–1239.
19. [19] Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J.G., Cornel, J.H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., Gullestad, L., Hjalmarson, A., Hradec, J., Jánosi, A., Kamenský, G., Komajda, M., Korewicki, J., Kuusi, T., Mach, F., Mareev, V., McMurray, J.J., Ranjith, N., Schaufelberger, M., Vanhaecke, J., van Veldhuisen, D.J., Waagstein, F., Wedel, H., Wikstrand, J., CORONA Group. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. 357 (2007), 2248–2261.
20. [20] Agustí, A., Edwards, L.D., Rennard, S.I., MacNee, W., Tal-Singer, R., Miller, B.E., Vestbo, J., Lomas, D.A., Calverley, P.M., Wouters, E., Crim, C., Yates, J.C., Silverman, E.K., Coxson, H.O., Bakke, P., Mayer, R.J., Celli, B., Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One, 7, 2012, e37483.
21. [21] Fabbri, L.M., Luppi, F., Beghe, B., Rabe, K.F., Complex chronic comorbidities of COPD. Eur. Respir. J. 31 (2008), 204–212.
22. [22] Cazzola, M., Bettoncelli, G., Sessa, E., Cricelli, C., Biscione, G., Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration 80 (2010), 112–119.
23. [23] Alexeeff, S.E., Litonjua, A.A., Sparrow, D., Vokonas, P.S., Schwartz, J., Statin use reduces decline in lung function: VA normative aging study. Am. J. Respir. Crit. Care Med. 176 (2007), 742–747 14.
24. [24] Lee, T.M., Chen, C.C., Shen, H.N., Chang, N.C., Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin. Sci. (Lond) 116 (2009), 497–505.
25. [25] Mancini, G.B., Etminan, M., Zhang, B., Levesque, L.E., FitzGerald, J.M., Brophy, J.M., Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J. Am. Coll. Cardiol. 47 (2006), 2554–2560.
26. [26] Søyseth, V., Brekke, P.H., Smith, P., Omland, T., Statin use is associated with reduced mortality in COPD. Eur. Respir. J. 29 (2007), 279–283.
27. [27] Lee, J.H., Lee, D.S., Kim, E.K., Choe, K.H., Oh, Y.M., Shim, T.S., Kim, S.E., Lee, Y.S., Lee, S.D., Simvastatin inhibits cigarette smoking–induced emphysema and pulmonary hypertension in rat lungs. Am. J. Respir. Crit. Care Med. 172 (2005), 987–993.
28. [28] Mathur, N., Ramasubbu, K., Mann, D.L., Spectrum of pleiotropic effects of statins in heart failure. Heart Fail Clin. 4 (2008), 153–161.
29. [29] Jain, M.K., Ridker, P.M., Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat. Rev. Drug Discov. 4 (2005), 977–987.
30. [30] Young, R.P., Hopkins, R., Eaton, T.E., Pharmacological actions of statins: potential utility in COPD. Eur. Respir. Rev. 18 (2009), 222–232.
31. [31] McMurray, J.J., Kjekshus, J., Gullestad, L., Dunselman, P., Hjalmarson, A., Wedel, H., Lindberg, M., Waagstein, F., Grande, P., Hradec, J., Kamenský, G., Korewicki, J., Kuusi, T., Mach, F., Ranjith, N., Wikstrand, J., CORONA study group. Effects of statin therapy according to plasma high-sensitivity C-Reactive protein concentration in the controlled rosuvastatin multinational trial in heart failure (CORONA). A retrospective analysis. Circulation 120 (2009), 2188–2196.
32. [32] Martinez, F.D., Early-life origins of chronic obstructive pulmonary disease. N. Engl. J. Med. 375 (2016), 871–878.
33. [33] Speizer, F.E., Ware, J.H., Exploring different phenotypes of COPD. N. Engl. J. Med. 373 (2015), 185–186.